U.S. markets closed

RegeneRx Biopharmaceuticals, Inc. (RGRX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2900-0.0047 (-1.59%)
At close: 2:21PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2947
Open0.2900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2900 - 0.2975
52 Week Range0.1800 - 0.8200
Volume9,190
Avg. Volume107,009
Market Cap38.729M
Beta (5Y Monthly)0.58
PE Ratio (TTM)N/A
EPS (TTM)-0.0110
Earnings DateAug 12, 2020 - Aug 17, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syndrome
    PR Newswire

    RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syndrome

    RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted a press release from its U.S. joint venture, ReGenTree LLC, on its website pursuant to the completed data analysis of its Phase 3 clinical trial (ARISE-3) with RGN-259 for the treatment of dry eye syndrome, as well as the results of pooling patient data from all three Phase 3 dry eye trials (ARISE-1, ARISE-2 and ARISE-3 comprising approximately 1,500 patients. The press release can be accessed by clicking on the following link: http://www.regenerx.com/image/ReGenTree_PR+%28MAY2021%29+FIN.pdf or navigating to RegeneRx's home page at www.RegeneRx.com.

  • RegeneRx Issues Update on ARISE-3 Trial
    PR Newswire

    RegeneRx Issues Update on ARISE-3 Trial

    RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information on its website regarding the estimated timing of the statistical and regulatory plan for its phase 3 dry eye clinical trial (ARISE-3). This summary was provided to RegeneRx by GtreeBNT, the operating entity of its U.S. joint venture, ReGenTree LLC and sponsor of the ARISE-3 trial, which was generated at GtreeBNT's shareholder meeting on Friday March 19, 2021: http://www.regenerx.com/March-22-2021-Update-on-ARISE-3-Statistical-and-Regulatory-Plan or navigate to RegeneRx's home page at http://www.regenerx.com.

  • RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial
    PR Newswire

    RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial

    RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage biopharmaceutical company focused on tissue protection, repair and regeneration, announced that the ARISE-3 Phase 3 clinical trial evaluating RGN-259 eyedrops for the treatment of dry eye syndrome did not meet its primary outcome measures. However, efficacy was seen in the improvement of ocular grittiness, one of the pre-specified secondary symptom endpoints in the trial. The statistically significant improvement was seen at one and two weeks after treatment, and post-exposure in a controlled adverse environment after two weeks of treatment with RGN-259 compared to placebo (p=0.0104, 0.0307, and 0.0046, respectively).